National Center of Neurology and Psychiatry;Chugai Seiyaku Kabushiki Kaisha
发明人:
申请号：
EP16796547.4
公开号：
EP3299810A4
申请日:
2016.05.19
申请国别(地区):
EP
年份:
2019
代理人:
摘要：
According to the present invention, the therapeutic effect of an IL-6 inhibitor on MS was found to be predictable by using as indicators the amount of plasmablasts and/or the indicator of change in immature plasmablasts (amount of immature plasmablasts or amount of follicular helper T cells) in MS patients with a large amount of plasmablasts. Furthermore, IL-6 inhibitors were found to be effective against MS in which plasmablasts occur at high levels and in which the indicator of change in immature plasmablasts is high. The present invention provides methods for selecting MS cases for which treatment with an IL-6 inhibitor is effective, and also provides an effective therapeutic method for patients with MS in which plasmablast occur at high levels and in which the indicator of change in immature plasmablasts is high.
